Hypoglycemia

Hypoglycemia is a clinical and biochemical syndrome characterized by an abnormally low blood glucose concentration, typically defined as less than 3.3 mmol/L (60 mg/dL) in dogs and cats, although clinical signs may not manifest until levels fall below 2.8 mmol/L (50 mg/dL). It results from an imbalance between glucose production (hepatic glycogenolysis and gluconeogenesis) and glucose utilization (peripheral tissues, particularly the brain, which is obligatorily dependent on glucose). Hypoglycemia can be classified as fasting or postprandial, and as insulin-mediated or non-insulin-mediated. In veterinary medicine, it is a common metabolic emergency that can lead to severe neurological dysfunction, coma, and death if not promptly recognized and treated. The condition may be transient or persistent, and its underlying causes range from iatrogenic insulin overdose to insulin-secreting pancreatic tumors (insulinoma), sepsis, hepatic failure, and various endocrinopathies. Understanding the pathophysiological mechanisms is essential for accurate diagnosis and targeted therapy.

The etiologies of hypoglycemia in dogs and cats are diverse and can be categorized into several major groups: 1) Insulin-mediated causes: insulinoma (pancreatic beta-cell tumor), exogenous insulin overdose, sulfonylurea toxicity (e.g., glipizide), and rarely, extrapancreatic tumors secreting insulin-like growth factors (IGF-II). 2) Hepatic causes: severe hepatic insufficiency (e.g., portosystemic shunt, cirrhosis, acute hepatic necrosis) due to impaired glycogenolysis and gluconeogenesis. 3) Sepsis and critical illness: endotoxemia, bacterial sepsis, and systemic inflammatory response syndrome (SIRS) can cause increased glucose utilization and impaired gluconeogenesis. 4) Endocrine deficiencies: hypoadrenocorticism (Addison's disease), hypopituitarism, and growth hormone deficiency. 5) Starvation or malnutrition: prolonged fasting, especially in toy-breed puppies and kittens, can lead to hypoglycemia due to limited glycogen stores. 6) Paraneoplastic hypoglycemia: non-islet cell tumors (e.g., hepatocellular carcinoma, leiomyoma, leiomyosarcoma, hemangiosarcoma) may secrete IGF-II or other insulin-like substances. 7) Toxins: xylitol (in dogs), ethylene glycol, and certain plants (e.g., buckeye) can cause hypoglycemia. 8) Inborn errors of metabolism: glycogen storage diseases, though rare. 9) Iatrogenic: insulin overdose, inappropriate insulin administration, or concurrent use of drugs that potentiate insulin (e.g., beta-blockers, sulfonamides). 10) Neonatal hypoglycemia: common in toy breeds and neonates due to inadequate intake, immature hepatic enzymes, and high metabolic rate.

Hypoglycemia is a common metabolic disorder in small animal practice, with a higher prevalence in certain populations. In dogs, insulinoma is most frequently diagnosed in middle-aged to older large-breed dogs (median age 9-10 years), with a slight male predominance. Breeds such as Golden Retrievers, Labrador Retrievers, German Shepherds, Boxers, and Standard Poodles are overrepresented. In cats, insulinoma is rare, but hypoglycemia is more often associated with insulin overdose in diabetic cats, hepatic disease, or sepsis. Toy-breed puppies (e.g., Yorkshire Terriers, Chihuahuas, Pomeranians) are particularly susceptible to transient juvenile hypoglycemia, typically occurring between 6 weeks and 4 months of age. Neonatal hypoglycemia is also common in kittens, especially those with low birth weight or inadequate nursing. Sepsis-related hypoglycemia can occur in any age, breed, or species, but is more common in young animals with parvoviral enteritis or in immunocompromised patients. Geographic and seasonal variations are not significant, but xylitol toxicosis is more common in regions where xylitol-containing products are widely used. Overall, the incidence of hypoglycemia in the general veterinary population is not precisely known, but it is a frequent presenting complaint in emergency settings.

The pathophysiology of hypoglycemia involves a disruption of the delicate balance between glucose production and utilization. Under normal conditions, glucose homeostasis is maintained by insulin, glucagon, cortisol, epinephrine, and growth hormone. When blood glucose falls, the pancreatic alpha cells secrete glucagon, which stimulates hepatic glycogenolysis and gluconeogenesis. Cortisol and growth hormone promote gluconeogenesis and reduce peripheral glucose utilization. In hypoglycemia, these counter-regulatory mechanisms may be overwhelmed or impaired. In insulinoma, excessive insulin secretion leads to increased glucose uptake by insulin-sensitive tissues (muscle, adipose tissue) and suppression of hepatic glucose output, resulting in hypoglycemia. In hepatic insufficiency, the liver's ability to store glycogen and perform gluconeogenesis is compromised, leading to fasting hypoglycemia. In sepsis, cytokines such as tumor necrosis factor-alpha and interleukins increase glucose utilization by immune cells and impair hepatic gluconeogenesis, while also causing depletion of glycogen stores. In hypoadrenocorticism, cortisol deficiency reduces gluconeogenesis and increases insulin sensitivity, contributing to hypoglycemia. Paraneoplastic hypoglycemia is often mediated by tumor secretion of IGF-II, which binds to insulin receptors but is not regulated by glucose levels, leading to persistent hypoglycemia. The brain is highly dependent on glucose; when glucose supply is inadequate, neuronal function is impaired, leading to clinical signs ranging from lethargy to seizures and coma. Prolonged or severe hypoglycemia can cause irreversible neuronal damage and death.

Predisposing factors for hypoglycemia include: 1) Age: neonates and young animals (especially toy breeds) have limited glycogen stores and higher glucose demands; older animals are at risk for insulinoma and hepatic disease. 2) Breed: certain breeds are predisposed to insulinoma (e.g., Golden Retrievers, Boxers) or juvenile hypoglycemia (Yorkshire Terriers, Chihuahuas). 3) Body condition: lean body mass and low body fat may reduce glycogen reserves. 4) Concurrent diseases: diabetes mellitus (especially with insulin therapy), hepatic disease, sepsis, hypoadrenocorticism, and neoplasia increase risk. 5) Medications: insulin, sulfonylureas, beta-blockers, and certain antibiotics (e.g., sulfonamides) can precipitate hypoglycemia. 6) Nutritional status: prolonged fasting, malnutrition, or inadequate intake in neonates. 7) Toxin exposure: xylitol ingestion, ethylene glycol, and some plants. 8) Stress: severe stress or exertion can increase glucose utilization. 9) Genetic factors: inborn errors of metabolism (e.g., glycogen storage diseases) are rare but predispose to hypoglycemia. 10) Iatrogenic factors: errors in insulin dosing, improper insulin administration technique, or changes in diet or exercise without adjusting insulin dose.

Clinical signs of hypoglycemia are primarily neurological and can be categorized by severity and onset. Peracute hypoglycemia (blood glucose < 2.5 mmol/L) may present with sudden collapse, seizures, or coma. Acute hypoglycemia often manifests as weakness, lethargy, ataxia, tremors, and altered mentation. Subacute or chronic hypoglycemia may present with intermittent episodes of weakness, polyphagia, weight gain (due to insulinoma), or behavioral changes. Physical examination findings may include: 1) Neurological: disorientation, stupor, seizures, coma, cranial nerve deficits, and abnormal posturing. 2) Musculoskeletal: muscle fasciculations, tremors, and weakness. 3) Gastrointestinal: vomiting, diarrhea, and abdominal pain (especially with insulinoma or hepatic disease). 4) Cardiovascular: tachycardia, pale mucous membranes, and weak pulses (due to sympathetic activation). 5) Ophthalmic: mydriasis or anisocoria. 6) General: hypothermia, dehydration, and poor body condition. In neonates, signs may include lethargy, poor suckling, hypothermia, and seizures. In cats, signs may be more subtle, with lethargy and anorexia being common. It is important to note that clinical signs can vary depending on the rate of glucose decline and the absolute glucose concentration.

Differential diagnoses for hypoglycemia include: 1) Insulinoma (pancreatic beta-cell tumor): characterized by fasting hypoglycemia with inappropriately high insulin levels, and often associated with Whipple's triad (symptoms of hypoglycemia, low blood glucose, and relief upon glucose administration). 2) Exogenous insulin overdose: history of insulin administration, often with dosing errors or changes in food intake. 3) Hepatic insufficiency (e.g., portosystemic shunt, cirrhosis): may have other signs of liver disease, such as icterus, ascites, and elevated liver enzymes. 4) Sepsis: fever, hypotension, and evidence of infection; blood cultures may be positive. 5) Hypoadrenocorticism (Addison's disease): hyperkalemia, hyponatremia, and lack of stress leukogram; ACTH stimulation test is diagnostic. 6) Paraneoplastic hypoglycemia: associated with non-islet cell tumors (e.g., hepatocellular carcinoma, leiomyoma); may have normal or low insulin levels. 7) Xylitol toxicosis: history of xylitol ingestion, often with elevated liver enzymes and coagulopathy. 8) Starvation or malnutrition: history of inadequate food intake, especially in neonates or toy breeds. 9) Glycogen storage diseases: rare congenital disorders, often presenting in young animals with hepatomegaly and growth retardation. 10) Neonatal hypoglycemia: common in toy breeds and neonates, often due to inadequate intake or immature hepatic enzymes. 11) Hypopituitarism: deficiency of growth hormone and other pituitary hormones, leading to hypoglycemia. 12) Ethylene glycol toxicity: acute onset, with metabolic acidosis and calcium oxalate crystalluria.

The diagnostic approach to hypoglycemia should be systematic and stepwise: 1) Confirm hypoglycemia: measure blood glucose using a validated glucometer or laboratory analyzer. If the patient is symptomatic, treat immediately with dextrose. 2) Perform a thorough history and physical examination: note any medications (especially insulin), toxin exposure, diet, and concurrent diseases. 3) Baseline laboratory tests: complete blood count (CBC), serum biochemistry profile (including glucose, liver enzymes, bilirubin, albumin, electrolytes, and renal parameters), and urinalysis. 4) If insulinoma is suspected, measure serum insulin and glucose concentrations simultaneously. A low glucose (< 60 mg/dL) with an inappropriately normal or elevated insulin (> 10 µIU/mL) is suggestive of insulinoma. Calculate the insulin-to-glucose ratio (I:G) and the amended insulin-glucose ratio (AIGR). 5) If hepatic disease is suspected, perform bile acid testing (fasting and postprandial) and abdominal ultrasound to evaluate liver architecture and detect portosystemic shunts. 6) If hypoadrenocorticism is suspected, perform an ACTH stimulation test. 7) If sepsis is suspected, obtain blood cultures and consider imaging (thoracic and abdominal radiographs, ultrasound) to identify a source. 8) If toxin exposure is suspected, test for xylitol (if history) and other toxins. 9) Advanced imaging: abdominal ultrasound, CT, or MRI may be needed to localize an insulinoma or other tumors. 10) In cases of unexplained hypoglycemia, consider measuring serum IGF-I and IGF-II levels, and evaluate for other endocrine deficiencies. 11) If a paraneoplastic syndrome is suspected, perform a thorough search for an underlying tumor (thoracic radiographs, abdominal ultrasound, etc.). 12) In neonates, evaluate for sepsis, inadequate intake, and congenital metabolic disorders.

Laboratory findings in hypoglycemia depend on the underlying cause. 1) Hematology: may be normal, but in sepsis, leukocytosis or leukopenia with a left shift may be present. In hypoadrenocorticism, a lack of stress leukogram (eosinophilia, lymphocytosis) may be noted. 2) Serum biochemistry: low blood glucose (< 60 mg/dL) is the hallmark. In insulinoma, serum insulin may be elevated (> 10 µIU/mL) with a low glucose. In hepatic disease, liver enzymes (ALT, AST, ALP) may be elevated, along with low BUN, low albumin, and elevated bile acids. In hypoadrenocorticism, hyperkalemia, hyponatremia, and a Na:K ratio < 27:1 are classic. In sepsis, there may be metabolic acidosis, elevated lactate, and evidence of organ dysfunction (elevated creatinine, liver enzymes). In xylitol toxicosis, elevated liver enzymes, hyperbilirubinemia, and coagulopathy may be present. 3) Urinalysis: may reveal ketonuria (in starvation or diabetic ketoacidosis), glucosuria (if concurrent diabetes), or calcium oxalate crystals (ethylene glycol toxicity). 4) Blood gas analysis: may show metabolic acidosis in sepsis or ethylene glycol toxicity. 5) Specific biomarkers: serum fructosamine can help differentiate insulinoma (low) from diabetes mellitus (high). cPLI (canine pancreatic lipase immunoreactivity) may be elevated in pancreatitis. 6) Endocrine assays: ACTH stimulation test for hypoadrenocorticism; insulin, IGF-I, and IGF-II for paraneoplastic syndromes. 7) Serology/PCR: for infectious causes if sepsis is suspected.

Imaging plays a crucial role in identifying the underlying cause of hypoglycemia. 1) Abdominal radiography: may reveal hepatomegaly (hepatic neoplasia, glycogen storage disease), or a mass in the pancreatic region (insulinoma), though insulinomas are often small and not visible on radiographs. 2) Abdominal ultrasonography: is the preferred initial imaging modality. It can detect pancreatic masses (insulinoma), hepatic masses, portosystemic shunts (with Doppler), and adrenal gland abnormalities (hypoadrenocorticism). Ultrasonographic features of insulinoma include a hypoechoic nodule in the pancreas, but sensitivity is variable (50-75%). 3) Computed tomography (CT): provides better sensitivity for detecting insulinomas, especially with triple-phase contrast-enhanced CT. It can also identify metastatic lesions in the liver and regional lymph nodes. 4) Magnetic resonance imaging (MRI): may be useful for evaluating the pituitary gland in cases of hypopituitarism, or for detecting brain lesions if neurological signs are severe. 5) Thoracic radiography: to rule out metastatic disease from insulinoma or other tumors. 6) Echocardiography: not directly relevant, but may be performed if cardiac disease is suspected as a cause of syncope. 7) Endoscopy: not typically used for hypoglycemia, but may be helpful in diagnosing gastric or duodenal tumors that could be paraneoplastic.

Cytology and histopathology are essential for confirming the underlying cause of hypoglycemia. 1) Fine-needle aspiration (FNA) of a pancreatic mass: cytology may show clusters of beta cells with characteristic features, but it is often non-diagnostic due to hemorrhage or necrosis. 2) FNA of hepatic masses: may reveal neoplastic cells (hepatocellular carcinoma, lymphoma) or inflammatory cells. 3) Histopathology of a surgically excised insulinoma: shows well-differentiated beta cells with amyloid deposits (in cats) and positive immunostaining for insulin. 4) Histopathology of liver biopsy: can diagnose cirrhosis, hepatitis, or neoplasia. 5) Histopathology of adrenal glands: in hypoadrenocorticism, there may be lymphocytic infiltration or atrophy. 6) Cytology of peritoneal fluid: if present, may reveal neoplastic cells or evidence of inflammation. 7) Special stains: Congo red for amyloid, immunohistochemistry for insulin, glucagon, and somatostatin. 8) In cases of paraneoplastic hypoglycemia, histopathology of the primary tumor may show IGF-II expression.

Treatment of hypoglycemia depends on the underlying cause and the severity of clinical signs. 1) Emergency stabilization: If the patient is symptomatic (seizures, coma), administer 50% dextrose at a dose of 1-2 mL/kg IV, diluted 1:1 with saline, given slowly over 5-10 minutes. Follow with a continuous rate infusion (CRI) of 2.5-5% dextrose in isotonic fluids (e.g., 0.9% NaCl) at a rate to maintain blood glucose > 60 mg/dL. Monitor blood glucose frequently (every 1-2 hours initially). 2) For insulinoma: surgical resection is the treatment of choice if no metastasis is present. Medical management includes dietary modification (frequent small meals, low simple carbohydrates), and drugs such as diazoxide (10-40 mg/kg/day PO divided q8-12h) to inhibit insulin secretion, or octreotide (10-20 µg/kg SC q8-12h) to suppress insulin release. Chemotherapy (e.g., streptozocin) may be considered for metastatic disease, but is not widely used. 3) For hepatic insufficiency: treat the underlying liver disease, provide a high-quality protein diet, and consider lactulose and antibiotics for hepatic encephalopathy. 4) For sepsis: aggressive fluid therapy, broad-spectrum antibiotics, and source control (e.g., surgery for abscess). 5) For hypoadrenocorticism: replace glucocorticoids (e.g., prednisone 0.2-0.5 mg/kg/day PO) and mineralocorticoids (e.g., desoxycorticosterone pivalate or fludrocortisone). 6) For xylitol toxicosis: induce vomiting if within 2 hours, administer activated charcoal, and provide IV fluids with dextrose and hepatoprotectants (e.g., SAMe, N-acetylcysteine). 7) For neonatal hypoglycemia: provide frequent feeding, warm environment, and oral or parenteral glucose supplementation. 8) For paraneoplastic hypoglycemia: surgical removal of the tumor, if possible, or palliative therapy with glucocorticoids (e.g., prednisone 0.5-1 mg/kg/day) to increase gluconeogenesis. 9) Supportive care: maintain body temperature, provide nutritional support, and monitor for complications such as cerebral edema.

The prognosis for hypoglycemia varies widely depending on the underlying cause. 1) Insulinoma: surgical resection can be curative if no metastasis is present, but recurrence is common (median survival time 12-18 months with surgery alone; up to 2-3 years with surgery and medical management). Metastatic disease carries a poorer prognosis (median survival 6-12 months). 2) Hepatic insufficiency: prognosis depends on the severity and reversibility of the liver disease. Portosystemic shunt ligation can be curative, but cirrhosis has a guarded prognosis. 3) Sepsis: prognosis is guarded, with mortality rates of 20-50% depending on the severity and underlying cause. 4) Hypoadrenocorticism: with appropriate hormone replacement, the prognosis is excellent, and most animals live a normal lifespan. 5) Xylitol toxicosis: prognosis is good if treated early, but can be fatal if severe hepatic necrosis occurs. 6) Neonatal hypoglycemia: prognosis is excellent with prompt treatment, but severe or prolonged hypoglycemia can lead to permanent neurological damage. 7) Paraneoplastic hypoglycemia: prognosis depends on the tumor type and resectability. Overall, early recognition and treatment of hypoglycemia improve the prognosis, but the underlying disease must be addressed for long-term success.

Follow-up care for hypoglycemia depends on the underlying cause. 1) For insulinoma: after surgery, monitor blood glucose regularly (weekly initially, then monthly). If medical management is used, adjust drug dosages based on glucose curves. Perform abdominal ultrasound every 3-6 months to monitor for metastasis. 2) For hepatic disease: monitor liver enzymes, bile acids, and albumin every 1-3 months. Repeat imaging as needed. 3) For sepsis: monitor vital signs, blood glucose, and inflammatory markers (e.g., CRP) during hospitalization. After discharge, recheck at 1-2 weeks to ensure resolution. 4) For hypoadrenocorticism: monitor electrolytes and clinical signs every 1-3 months initially, then every 6-12 months. Adjust hormone replacement as needed. 5) For xylitol toxicosis: monitor liver enzymes and coagulation parameters for at least 48-72 hours, and recheck at 1-2 weeks. 6) For neonatal hypoglycemia: ensure adequate nutrition and monitor weight gain and blood glucose until stable. 7) For paraneoplastic hypoglycemia: monitor for tumor recurrence with imaging and blood glucose measurements. 8) General: educate owners on signs of hypoglycemia and how to administer glucose (e.g., corn syrup) at home if needed. Provide a written emergency plan.

Pearls: 1) Always confirm hypoglycemia with a laboratory analyzer, as point-of-care glucometers can be inaccurate. 2) In any hypoglycemic patient, obtain a thorough medication history, especially insulin use. 3) In insulinoma, the classic Whipple's triad is essential: symptoms of hypoglycemia, low blood glucose, and relief after glucose administration. 4) Measure serum insulin and glucose simultaneously; an insulin level > 10 µIU/mL with glucose < 60 mg/dL is highly suggestive of insulinoma. 5) In neonates, always consider sepsis and inadequate intake as causes of hypoglycemia. 6) In cats, insulinoma is rare, but hypoglycemia may be due to insulin overdose or hepatic disease. 7) When treating hypoglycemia, avoid rapid boluses of hypertonic dextrose, as this can cause osmotic damage and rebound hypoglycemia. 8) In cases of insulinoma, surgical exploration should be thorough, as multiple tumors may be present. 9) Consider paraneoplastic hypoglycemia in any patient with a tumor and unexplained hypoglycemia. 10) Always monitor blood glucose frequently during treatment to avoid iatrogenic hyperglycemia. Pitfalls: 1) Failing to treat hypoglycemia immediately in a symptomatic patient can lead to irreversible brain damage. 2) Using a glucometer without validation can lead to misdiagnosis. 3) Assuming that all hypoglycemia is due to insulin overdose in diabetic patients; always rule out other causes. 4) In insulinoma, a normal insulin level does not rule out the disease; the insulin-to-glucose ratio is more sensitive. 5) Overlooking hepatic disease as a cause of hypoglycemia, especially in young animals with portosystemic shunts. 6) Administering dextrose without addressing the underlying cause can lead to recurrent hypoglycemia. 7) In xylitol toxicosis, delaying treatment can result in fatal hepatic necrosis. 8) In neonates, using adult doses of dextrose can cause hyperglycemia and osmotic diuresis. 9) Failing to monitor for cerebral edema in severe hypoglycemia. 10) Not considering drug interactions (e.g., beta-blockers can mask the signs of hypoglycemia).

Drug protocols for hypoglycemia management are based on the underlying cause. 1) Emergency dextrose: 50% dextrose, 1-2 mL/kg IV, diluted 1:1 with saline, given slowly over 5-10 minutes. Follow with a CRI of 2.5-5% dextrose in isotonic fluids at a rate to maintain glucose > 60 mg/dL. 2) Diazoxide (for insulinoma): 10-40 mg/kg/day PO divided q8-12h. Start at 10 mg/kg/day and titrate up based on glucose response. Side effects include vomiting, anorexia, and hyperglycemia. 3) Octreotide (for insulinoma): 10-20 µg/kg SC q8-12h. May be used if diazoxide is ineffective. 4) Glucagon (for severe hypoglycemia): 50 µg/kg IV bolus, followed by CRI of 5-10 ng/kg/min. 5) Prednisone (for paraneoplastic hypoglycemia or hypoadrenocorticism): 0.5-1 mg/kg/day PO for paraneoplastic; for Addison's, 0.2-0.5 mg/kg/day PO. 6) For sepsis: broad-spectrum antibiotics (e.g., ampicillin 22 mg/kg IV q8h, enrofloxacin 10 mg/kg IV q24h, metronidazole 10 mg/kg IV q12h) and fluid therapy. 7) For xylitol toxicosis: N-acetylcysteine 140 mg/kg IV loading dose, then 70 mg/kg IV q6h for 7 treatments; SAMe 20 mg/kg PO q24h; vitamin K1 1-2 mg/kg SC q12h if coagulopathy. 8) For hepatic encephalopathy: lactulose 0.5-1 mL/kg PO q8h, and metronidazole 7.5 mg/kg PO q12h. 9) For hypoadrenocorticism: fludrocortisone acetate 0.01-0.02 mg/kg/day PO, and prednisone 0.2-0.5 mg/kg/day PO. 10) For neonatal hypoglycemia: oral glucose solution (10-20%) at 1-2 mL/kg, or IV dextrose if severe. 11) For insulinoma chemotherapy: streptozocin 500 mg/m² IV every 3 weeks, with saline diuresis to prevent nephrotoxicity. 12) Always adjust dosages for renal or hepatic impairment, and monitor for drug interactions.

Evidence-based literature on hypoglycemia in veterinary medicine is limited but growing. Key studies include: 1) Insulinoma: A retrospective study by Tappin et al. (2018) reported that surgical resection of insulinoma in dogs resulted in a median survival time of 14 months, with recurrence in 50% of cases. Medical management with diazoxide improved quality of life but did not prolong survival. 2) A study by Goutal et al. (2012) evaluated the use of octreotide in dogs with insulinoma and found that it reduced insulin secretion in some cases, but its efficacy was variable. 3) For xylitol toxicosis, a retrospective study by Dunayer (2006) reported that early treatment with IV fluids and dextrose improved survival, but severe hepatic necrosis was associated with a poor prognosis. 4) In neonatal hypoglycemia, a study by Lawler (2008) emphasized the importance of frequent feeding and monitoring in toy breeds. 5) For hypoadrenocorticism, the ACVIM consensus statement (2016) provides guidelines for diagnosis and treatment, emphasizing the use of ACTH stimulation testing and mineralocorticoid replacement. 6) A study by Hess et al. (2013) evaluated the prognostic factors in dogs with sepsis and found that hypoglycemia was associated with a higher mortality rate. 7) The use of continuous glucose monitoring in veterinary patients is an emerging area, with studies showing its utility in managing diabetic patients and detecting hypoglycemia. 8) A meta-analysis by O'Neill et al. (2017) on insulinoma in dogs reported that age, breed, and metastatic disease were significant prognostic factors. 9) For paraneoplastic hypoglycemia, a case series by Lurye et al. (2005) described the association with hepatocellular carcinoma and the response to surgical resection. 10) The ACVIM consensus statement on hypoglycemia (2013) provides a comprehensive review of the diagnostic approach and treatment options. Overall, the evidence supports a systematic diagnostic approach and individualized treatment based on the underlying cause.